ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA

Intellia Therapeutics (NTLA) PT Lowered to $50 at Truist Securities

March 3, 2025 11:55 AM EST

Truist Securities analyst Joon Lee lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $50.00 (from $90.00) while maintaining a Buy rating.

The analyst comments "4Q24: Restructuring underway should help extend operational runway into 1H27 as NTLA-2002 is poised to be the historic first in... More